Paul Secrist

Company: Cyteir Therapeutics
Job title: Chief Scientific Officer
Seminars:
Targeting RAD51-Mediated Homologous Recombination as a Novel Therapeutic Approach to Treating Cancer Patients 12:15 pm
day: Day Two
Company: Cyteir Therapeutics
Job title: Chief Scientific Officer
day: Day Two